Compare Neurocrine Biosciences Inc (NBIX) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Neurocrine Biosciences Inc trades at $136.25 (market cap $13.82B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.44B). The key difference: Neurocrine Biosciences Inc is far larger — about 4× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.07% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 24 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| NBIX | ZGN | |
|---|---|---|
Market Cap | $13.82B | $3.44B |
Volume | 1,506,669 | 781,107 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $15.25 |
52-Week Low | $123.10 | $8.69 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $13.83B | $4.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 19.87 and robust profitability, including a net income margin of 20.91% and three consecutive quarterly earnings beats. Recent news highlights pipeline progress and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive given strong earnings momentum and product growth, but risks include execution challenges and pricing pressures. The current price offers a significant discount to the analyst target, presenting a potential opportunity for investors comfortable with the biopharmaceutical sector's inherent volatility.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
